STOCK TITAN
  1. Home
  2. Sec-filings
  3. CADL
  4. [Form 4] Candel Therapeutics, Inc. Insider Trading Activity

Candel Therapeutics (CADL) CTO sells 7,000 shares via 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Candel Therapeutics, Inc. (CADL) reported that Chief Technology Officer Tyagarajan Seshu sold 7,000 shares of common stock at $12.00 per share on 2026-08-17 in an open-market or private transaction. Following this sale, Seshu directly held 76,865 shares of Candel Therapeutics common stock. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on 3/16/2026.

Positive

  • None.

Negative

  • None.
Insider Tyagarajan Seshu
Role Chief Technology Officer
Sold 7,000 shs ($84K)
Type Security Shares Price Value
Sale Common Stock F1 7,000 $12.00 $84K
Holdings After Transaction: Common Stock — 76,865 shares (Direct)
Footnotes (1)
  1. F1. This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026.
Shares sold 7,000 shares Common stock sale reported by CTO Tyagarajan Seshu on 2026-08-17
Sale price per share $12.00 per share Price for the 7,000 CADL common shares sold on 2026-08-17
Shares held after transaction 76,865 shares Direct holdings of CADL common stock by Tyagarajan Seshu after the sale
10b5-1 plan adoption date 3/16/2026 Adoption date of the Rule 10b5-1 trading plan governing the reported sale
Rule 10b5-1 trading plan regulatory
"transaction was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open market or private transaction financial
"transaction_code_description: Sale in open market or private transaction"
Form 4 regulatory
"This transaction reported on this Form 4 was effected pursuant to a 10b5-1"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did CADL report for Tyagarajan Seshu?
Candel Therapeutics reported that CTO Tyagarajan Seshu sold 7,000 shares of CADL common stock. The shares were sold at $12.00 per share in an open-market or private transaction on 2026-08-17.

How many Candel Therapeutics (CADL) shares does Tyagarajan Seshu hold after this sale?
After the reported sale, Tyagarajan Seshu directly holds 76,865 shares of Candel Therapeutics common stock. This post-transaction holding reflects his remaining direct ownership following the 7,000-share sale on 2026-08-17.

At what price were the CADL shares sold in Tyagarajan Seshu’s Form 4 filing?
The reported sale of Candel Therapeutics (CADL) common stock by Tyagarajan Seshu was executed at $12.00 per share. The transaction involved 7,000 shares of common stock in an open-market or private transaction on 2026-08-17.

Was Tyagarajan Seshu’s CADL stock sale under a Rule 10b5-1 plan?
Yes, the 7,000-share sale by Tyagarajan Seshu was effected pursuant to a Rule 10b5-1 trading plan. The footnote states the plan was adopted on 3/16/2026, indicating the trades followed that pre-arranged instruction.

What role does Tyagarajan Seshu hold at Candel Therapeutics (CADL)?
Tyagarajan Seshu is the Chief Technology Officer of Candel Therapeutics, Inc. His Form 4 filing reports a personal transaction in CADL common stock, specifically a 7,000-share sale executed on 2026-08-17.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tyagarajan Seshu
(Last)(First)(Middle)
C/O CANDEL THERAPEUTICS, INC.
117 KENDRICK ST., SUITE 450
(Street)
NEEDHAM MASSACHUSETTS 02494
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Candel Therapeutics, Inc. [ CADL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Technology Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/17/2026S(1)7,000D$1276,865D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 3/16/2026.
/s/ Charles Schoch, as Attorney-in-Fact for Seshu Tyagarajan08/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR